UCSF selects evo® Smart Shipper for clinical Treg Cell trials
Critical Phase 1 research to advance treatment for autoimmune, cardiovascular, neurological diseases
Savsu Technologies is pleased to announce that our evo® Cold Chain 2.0 System has been selected for eight active and pending clinical trials at the University of California, San Francisco (UCSF) Diabetes Center and Department of Surgery. Savsu’s evo system will be used in conjunction with BioLife's hypothermic storage and cryopreservation freeze media in the important Phase 1 trials investigating effective cold chain management for the distribution of regulatory T cells known as Tregs.
The evo® Cold Chain 2.0 system was chosen in a rigorous evaluation process to determine the best method for temperature regulation and logistics visibility of high-value shipments of source material.
Bruce McCormick, President of SAVSU, stated, "We are honored that the Diabetes Center and the Department of Surgery at UCSF have selected our evo Smart Shipper technologies. We specifically designed the evo Smart Shipper to improve cold chain logistics and transport survival of small payload cellular therapies such as Tregs."
In an announcement, Jeffrey Bluestone, Ph.D.. the A.W. and Mary Margaret Clausen Distinguished Professor of Metabolism and Endocrinology and Director of the Hormone Research Institute in the Diabetes Center, commented, "Tregs hold great promise as treatments for autoimmune diseases such as diabetes, rheumatoid arthritis and lupus, and even as therapies for cardiovascular disease, neurological diseases and obesity. Effective cold chain management is an important potential component for commercial distribution of these novel cell-based therapies if approved."
Savsu recognizes both the importance and the special challenges of early phase trials and have designed our “evo Phase 1”program to support leading research institutions such as UCSF while significantly reducing operational risk.
For more information about our evo Phase1 program please contact us.